# Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer

> **NCT00480597** · PHASE2 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 141 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin
- **DRUG:** vinorelbine
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00480597
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2010-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00480597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00480597, "Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00480597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*